Catalyst Biosciences, Inc.
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
Last updated:
Abstract:
Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
Status:
Grant
Type:
Utility
Filling date:
19 Feb 2021
Issue date:
8 Mar 2022